Physician profile
Emily Pott
NPI 1770746299
$885.08
in general payments reported to CMS, 2019-2025
10 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $281 · 2024: $195 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $428.61 | 2023-2025 | Dailies Total1, Tryptyr, Precision 1 |
| Bausch & Lomb Americas INC. | $161.05 | 2023-2025 | Vyzulta, Miebo, Alden Scleral Zenlens |
| Sun Pharmaceutical Industries INC. | $69.83 | 2023-2025 | Cequa |
| Coopervision INC. | $61.21 | 2024-2025 | Clariti Contact Lens, Myday Contact Lens, Paragon Crt |
| Mallinckrodt Hospital Products INC. | $39.19 | 2023-2024 | Acthar |
| Harrow Eye, LLC | $34.92 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $30.10 | 2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Vision Care, INC. | $22.74 | 2024 | |
| Dompe US, INC. | $20.76 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $16.67 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Pott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.